Abstract
The principles of our current drug susceptibility testing (DST) for tuberculosis (TB) have already been laid out in 1963. Since then, DST has not gained much popularity owing to the long turn-around time and the introduction of potent antituberculosis drug regimens. These and other barriers have led to a critical gap in laboratory capacity in DST of Mycobacterium tuberculosis. However, owing to the emergence of multidrug resistant tuberculosis there is a pressing need for adequate and rapid DST.
In recent years, methods for fastening the diagnosis of drug resistant tuberculosis have been developed. Semi-automated (non)- radiometric liquid culture systems reduced the turn-around-time significantly. With the introduction of molecular diagnostic methods, such as reverse line probes and the recently introduced semi-automated real-time PCR, the turn-around time of at least an indicative resistance testing has dropped from days to hours. However, much more can be gained in the development of fast phenotypic and molecular DST methodologies. Recently also pharmacodynamic studies have also added significantly to our understanding of resistance development in tuberculosis treatment.
This article provides an overview of the most important DST techniques now available, with their characteristics, biosafety aspects, reproducibility and required quality control. Also the findings in pharmacodynamic studies and required future research are discussed. We will argue that drug susceptibility testing in TB treatment is an essential tool for adequate TB control and prevention of resistance and should be applied to all patients to guide TB treatment. Perhaps in the near future even individualized treatment doses could be an important help to prevent further emergence or further development of resistance.
Keywords: Tuberculosis, review, microbial sensitivity tests, multidrug resistant tuberculosis, antitubercular agents, pyrazinamide, pncA gene, moxifloxacine, streptomycin, point mutations
Current Pharmaceutical Design
Title: Drug Susceptibility Testing for Optimizing Tuberculosis Treatment
Volume: 17 Issue: 27
Author(s): Sami O. Simons and Dick van Soolingen
Affiliation:
Keywords: Tuberculosis, review, microbial sensitivity tests, multidrug resistant tuberculosis, antitubercular agents, pyrazinamide, pncA gene, moxifloxacine, streptomycin, point mutations
Abstract: The principles of our current drug susceptibility testing (DST) for tuberculosis (TB) have already been laid out in 1963. Since then, DST has not gained much popularity owing to the long turn-around time and the introduction of potent antituberculosis drug regimens. These and other barriers have led to a critical gap in laboratory capacity in DST of Mycobacterium tuberculosis. However, owing to the emergence of multidrug resistant tuberculosis there is a pressing need for adequate and rapid DST.
In recent years, methods for fastening the diagnosis of drug resistant tuberculosis have been developed. Semi-automated (non)- radiometric liquid culture systems reduced the turn-around-time significantly. With the introduction of molecular diagnostic methods, such as reverse line probes and the recently introduced semi-automated real-time PCR, the turn-around time of at least an indicative resistance testing has dropped from days to hours. However, much more can be gained in the development of fast phenotypic and molecular DST methodologies. Recently also pharmacodynamic studies have also added significantly to our understanding of resistance development in tuberculosis treatment.
This article provides an overview of the most important DST techniques now available, with their characteristics, biosafety aspects, reproducibility and required quality control. Also the findings in pharmacodynamic studies and required future research are discussed. We will argue that drug susceptibility testing in TB treatment is an essential tool for adequate TB control and prevention of resistance and should be applied to all patients to guide TB treatment. Perhaps in the near future even individualized treatment doses could be an important help to prevent further emergence or further development of resistance.
Export Options
About this article
Cite this article as:
O. Simons Sami and van Soolingen Dick, Drug Susceptibility Testing for Optimizing Tuberculosis Treatment, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470255
DOI https://dx.doi.org/10.2174/138161211797470255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: New Drug Targets for the Treatment of Asthma (Guest Editor: D. Knight)]
Current Drug Targets One-Pot Glycosylation Strategy for Rapid Access of Oligosaccharides with Wide Range of Molecular Diversity
Current Organic Chemistry New Aminoacyl-tRNA Synthetase Inhibitors as Antibacterial Agents
Current Drug Targets - Infectious Disorders Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies
Current Drug Therapy Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs
Infectious Disorders - Drug Targets Eight Stranded β -Barrel and Related Outer Membrane Proteins: Role in Bacterial Pathogenesis
Protein & Peptide Letters Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery PET Imaging for Gene & Cell Therapy
Current Gene Therapy Malaria and Leishmaniasis: Current Status of Chemotherapy, New Leads and Targets for Drug Discovery
Anti-Infective Agents in Medicinal Chemistry A Novel Multi-Target Drug Screening Strategy Directed Against Key Proteins of DAPk Family
Combinatorial Chemistry & High Throughput Screening Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria
Current Computer-Aided Drug Design Recent Synthesis of Marine Natural Products with Antibacterial Activities
Anti-Infective Agents in Medicinal Chemistry Coumarine Analogues with Antimycobacterial and Immunomodulatory Activity
Current Bioactive Compounds Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Recent Advances and Patents on Solid Lipid Nanoparticles
Recent Patents on Drug Delivery & Formulation An Efficient Gram Scale Synthesis of Aryl Iodides from Aryl Diazofluoroborates in Water under Mild Conditions
Letters in Organic Chemistry Targeting Intracellular Targets
Current Drug Delivery Evaluation of Molecular Docking Using Polynomial Empirical Scoring Functions
Current Drug Targets